Table 2.
Clinical characteristics and health service utilization among adherent statin users prior to admission.
| Characteristics | Statin continuation (N = 232) |
Non-continuation (N = 401) |
p value | ||
|---|---|---|---|---|---|
| N /median |
% /IQR |
N /median |
% /IQR |
||
| Comorbidities (during admission) | |||||
| Charlson score (median and IQR) | 2 | 1–4 | 2 | 0–3 | 0.5708 |
| Elixhauser score (median and IQR) | 4 | 3–6 | 4 | 3–6 | 0.3973 |
| Chronic renal disease | 61 | 26.29 | 78 | 19.45 | 0.0451 |
| Coagulation and hemorrhagic disorders | 27 | 11.64 | 84 | 20.95 | 0.0030 |
| Coagulopathy | 25 | 10.78 | 75 | 18.70 | 0.0084 |
| Congestive heart failure nonhypertensive | 64 | 27.59 | 60 | 14.96 | 0.0001 |
| Coronary atherosclerosis and other heart diseases | 87 | 37.50 | 115 | 28.68 | 0.0218 |
| Diabetes mellitus with complication | 61 | 26.29 | 69 | 17.21 | 0.0064 |
| Dyslipidemia including hyperlipidemia | 161 | 69.40 | 208 | 51.87 | <0.0001 |
| Infective arthritis | 15 | 6.47 | 11 | 2.74 | 0.0230 |
| Liver disease | 12 | 5.17 | 47 | 11.72 | 0.0063 |
| Malignant neoplasm | 6 | 2.59 | 54 | 13.47 | <0.0001 |
| Metastatic cancer | 3 | 1.29 | 30 | 7.48 | 0.0003 |
| Mild liver disease | 11 | 4.74 | 40 | 9.98 | 0.0197 |
| Obesity | 69 | 29.74 | 83 | 20.70 | 0.0103 |
| Poisoning by medication and drugs | 20 | 8.62 | 69 | 17.21 | 0.0027 |
| Solid tumor without metastasis | 5 | 2.16 | 49 | 12.22 | <0.0001 |
| Weight loss | 22 | 9.48 | 68 | 16.96 | 0.0095 |
| Medication use (during admission) | |||||
| Anti-hypertensive medication | 207 | 89.22 | 274 | 68.33 | <0.0001 |
| Comorbidities (6 months prior to admission) | |||||
| Charlson score (median and IQR) | 3 | 1–5 | 3 | 2–6 | 0. 9720 |
| Elixhauser score (median and IQR) | 6 | 5–9 | 5 | 3–9 | 0.7992 |
| History of any cancer | 35 | 15.09 | 102 | 25.44 | 0.0023 |
| History of chronic kidney disease | 47 | 20.26 | 57 | 14.21 | 0.048 |
| History of condition with dizziness or vertigo | 32 | 13.79 | 25 | 6.23 | 0.0014 |
| History of dyslipidemia including hyperlipidemia | 175 | 75.43 | 263 | 65.59 | 0.0097 |
| History of history of other Immunocompromise | 14 | 6.03 | 46 | 11.47 | 0.0244 |
| History of maintenance chemotherapy radiotherapy | 8 | 3.45 | 43 | 10.72 | 0.0012 |
| History of malignant neoplasm | 24 | 10.34 | 76 | 18.95 | 0.0042 |
| History of metastatic cancer | 7 | 3.02 | 37 | 9.23 | 0.0031 |
| History of other and ill-defined cerebrovascular diseases | 15 | 6.47 | 12 | 2.99 | 0.0372 |
| History of other eye disorder | 27 | 11.64 | 28 | 6.98 | 0.0451 |
| History of solid tumor without metastasis | 24 | 10.34 | 74 | 18.45 | 0.0066 |
| Medication use history (6 months prior to admission) | |||||
| History of diabetic medication | 74 | 31.9 | 112 | 27.93 | 0.0081 |
| History of anti-hypertensive medication | 199 | 85.78 | 317 | 79.05 | 0.0357 |
Data are median and interquartile range (IQR) or number and percent of patients.